Topical corticosteroids in the treatment of acute sunburn: A randomized, double-blind clinical trial

Archives of Dermatology

Volumn 144, Issue 5, 2008, Pages 620-624

  Faurschou, Annesofie ^a   Wulf, Hans C ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; CORTICOSTEROID; HYDROCORTISONE BUTYRATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENCY; ERYTHEMA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL; SUNBURN; ULTRAVIOLET B RADIATION;

ACUTE DISEASE; ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; CLOBETASOL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHEMA; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; SUNBURN; TREATMENT FAILURE;

EID: 44249096561     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.144.5.620     Document Type: Article

References (15)

1. Matsumura Y, Ananthaswamy HN. Short-term and long-term cellular and molecular events following UV irradiation of skin: implications for molecular medicine. Expert Rev Mol Med. 2002;4(26):1-22.
2. Rhodes LE, Belgi G, Parslew R, McLoughlin L, Clough GF, Friedmann PS. Ultraviolet B-induced erythema is mediated by nitric oxide and prostaglandin E2 in combination. J Invest Dermatol. 2001;117(4):880-885.
3. Andersen PH, Abrams K, Bjerring P, Maibach H. A time-correlation study of ultraviolet B-induced erythema measured by reflectance spectroscopy and laser Doppler flowmetry. Photodermatol Photoimmunol Photomed. 1991;8(3):123-128.
4. Han A, Maibach HI. Management of acute sunburn. Am J Clin Dermatol. 2004;5(1):39-47.
5. Duteil L, Queille-Roussel C, Lorenz B, Thieroff-Ekerdt R, Ortonne JP. A randomized, controlled study of the safety and efficacy of topical corticosteroid treatments of sunburn in healthy volunteers. Clin Exp Dermatol. 2002;27(4):314-318.
6. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988;124(6):869-871.
7. Wulf HC, Lock-Andersen J; Scandinavian Photodermatology Research Group. Standard erythema dose. Skin Res Technol. 1996;4:192.
8. Lock-Andersen J, Wulf HC. Threshold level for measurement of UV sensitivity: reproducibility of phototest. Photodermatol Photoimmunol Photomed. 1996;12(4):154-161.
9. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol. 1962;86:608-610.
10. US Dept of Health and Human Services, Food and Drug Administration. Guidance for industry: topical dermatologic corticosteroids: in vivo bioequivalence. http://www.fda.gov/ohrms/dockets/dockets/04p0206/04p-0206- ref0001-08-FDAGuidance-for-Industry-06-1995-vol3.pdf. Accessed January 2007.
11. Demana PH, Smith EW, Walker RB, Haigh JM, Kanfer I. Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing. Pharm Res. 1997;14(3):303-308.
12. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J. 2006;27(2):413-426.
13. Cals-Grierson MM, Ormerod AD. Nitric oxide function in the skin. Nitric Oxide. 2004;10(4):179-193.
14. Barr RM, Walker SL, Tsang W, et al. Suppressed alloantigen presentation, increased TNF-alpha, IL-1, IL-1Ra, IL-10, and modulation of TNF-R in UV-irradiated human skin. J Invest Dermatol. 1999;112(5):692-698.
15. Bech-Thomsen N, Ravnborg L, Wulf HC. A quantitative study of the melanogenic effect of multiple suberythemal doses of different ultraviolet radiation sources. Photodermatol Photoimmunol Photomed. 1994;10(2):53-56.